Publications by authors named "M S Seshadri"
Article Synopsis
- - A new approach to cancer treatment is emerging, focusing on developing therapies throughout all stages of cancer, using various preclinical models to test these treatments.
- - The research emphasizes the complexity of cancer, which includes genetic mutations and changes in cell behavior, and involves collaborations among experts at the National Cancer Institute to share insights on preclinical modeling.
- - The authors outline the strengths and weaknesses of different cancer models, proposing a roadmap and initial suggestions for using advanced preclinical models to improve strategies for cancer prevention and treatment.
Naringin (NAR), a flavanone glycoside, occurs widely in citrus fruits, vegetables, and alcoholic beverages. Despite evidence of the neuroprotective effects of NAR on animal models of ischemic stroke, brain cell-type-specific data about the antioxidant efficacy of NAR and possible protein targets of such beneficial effects are limited. Here, we demonstrate the brain cell type-specific prophylactic role of NAR, an FDA-listed food additive, in an in vitro oxygen-glucose deprivation (OGD) model of cerebral ischemia using MTT and DCFDA assays.
View Article and Find Full Text PDFArticle Synopsis
- This study investigates Ho-doped Ca(VO) phosphors intended for use in solid-state lighting, utilizing an optimized citrate-based sol-gel process to create desirable sheet-like structures.
- The research identifies a significant UV absorption at 371 nm, a corresponding band gap of 3.28 eV, and confirms robust green emission at 541 nm when excited at 451 nm, with optimal doping at 0.05 mol.
- The analysis includes concentration quenching due to dipole-dipole interactions and calculated Judd-Ofelt parameters, indicating that these phosphors have promising characteristics for efficient green-emitting devices in lighting and display technologies.
Article Synopsis
- Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different forms of the same disease, with similar treatment approaches.
- Prognostic factors such as undetectable minimal residual disease after treatment can significantly predict better survival outcomes for patients.
- Treatment decisions depend on disease characteristics, genetic mutations, age, overall health, and the side effects of the treatments, as detailed in the NCCN Guidelines.